Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Low-Dose Danazol for the Treatment of Telomere Related Diseases

Phase 2

Recruiting

Conditions: Telomere Disease

Interventions: Drug: Danazol

First Posted Date: 2017-10-17

Last Posted Date: 2025-06-13

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 40

Registration Number: NCT03312400

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Discovery of Sirolimus Sensitive Biomarkers in Blood

Phase 2

Completed

Conditions: Lymphangioleiomyomatosis

Interventions: Drug: Sirolimus 2mg

First Posted Date: 2017-10-09

Last Posted Date: 2025-04-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 33

Registration Number: NCT03304678

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments

Not Applicable

Recruiting

Conditions: Obesity

First Posted Date: 2017-09-20

Last Posted Date: 2025-06-13

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 325

Registration Number: NCT03288207

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)

Completed

Conditions: Coronary Disease
Myocardial Ischemia
Arteriosclerosis
Coronary Artery Disease
Arterial Occlusive Diseases

First Posted Date: 2017-08-18

Last Posted Date: 2025-01-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 36

Registration Number: NCT03253692

Locations: 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Plerixafor

First Posted Date: 2017-07-24

Last Posted Date: 2023-09-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 15

Registration Number: NCT03226691

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Extracellular RNAs in Relation to Cardiometabolic Risk

Completed

Conditions: Subclinical Atherosclerotic Cardiovascular Disease
Obesity
Blood Pressure

First Posted Date: 2017-07-21

Last Posted Date: 2023-12-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 4495

Registration Number: NCT03225196

Locations: 🇺🇸
Framingham Heart Study, Framingham, Massachusetts, United States

RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2

Completed

Conditions: Cardiovascular Disease
Hypertension

First Posted Date: 2017-07-21

Last Posted Date: 2022-06-15

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1700

Registration Number: NCT03225183

Locations: 🇺🇸
Framingham Heart Study, Framingham, Massachusetts, United States

Eltrombopag for People With Fanconi Anemia

Phase 2

Active, not recruiting

Conditions: Fanconi Anemia

Interventions: Drug: Eltrombopag

First Posted Date: 2017-07-02

Last Posted Date: 2025-06-13

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 25

Registration Number: NCT03206086

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2

Active, not recruiting

Conditions: Leukemia, Chronic Lymphatic
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphocytic Leukemia, Chronic, B Cell
Lymphocytic Leukemia, Chronic, B-Cell
B-Cell Chronic Lymphocytic Leukemia
B-Lymphocytic Leukemia, Chronic
Chronic Lymphocytic Leukemia
Leukemia, Chronic Lymphocytic, B-Cell
Leukemia, Lymphocytic, Chronic

Interventions: Drug: Ibrutinib
Drug: Fludarabine
Drug: Pembrolizumab

First Posted Date: 2017-06-29

Last Posted Date: 2023-11-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 15

Registration Number: NCT03204188

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome

Phase 1

Recruiting

Conditions: Hypo-Plastic MDS
Myelodysplastic Syndrome (MDS)
Severe Aplastic Anemia

Interventions: Biological: Omidubicel (former CordIn)
Device: Miltenyi CliniMACS(R) CD34 Reagent System

First Posted Date: 2017-06-02

Last Posted Date: 2025-06-27

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 37

Registration Number: NCT03173937

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy